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Introduction:  Prostate cancer is the most commonly diagnosed cancer in men and 
second leading cause of cancer deaths. Studies have shown that tRNA fragments are 
upregulated in prostate cancers and play important roles in carcinogenesis. This project 
looks at how tRNA cleaving enzyme angiogenin expression is regulated in prostate 
cancer tissues. 
Methods: Clinical data and mRNA expression levels of selected tRNA cleaving 
enzymes were extracted from the TCGA website. mRNAs were sequenced using 
IlluminaGA_RNASeqV2 at University of North Carolina.  
Results: 546 samples from 494 patients, with normal tissue from 53 patients were 
collected. ANG mRNA levels were lower in patients with higher Gleason 
scores(Intercept=1321.787362, regression coefficient= -87.05499452, R2=0.038). ANG 
mRNA levels were inconclusive in different clinical T grade(p=0.15), but were lower in 
higher pathologic T grade(intercept=1100.484695, x variable=-166.9047227, R2=0.038); 
2 
ANG expression was lower in patients with nodal involvement versus without(539.56 vs 
673.58, p=0.005).  
Discussion: Overall trend we found from the results were ANG mRNA expression 
levels are down regulated in patients that have more advanced disease versus early 
disease. This supports the hypothesis that ANG expression plays an interesting role in 
prostate cancer biology. This trend might be due to the negative feedback due to high 
levels of tRNA fragments however there is no single theory available to answer this 
question.  
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